Pertuzumab: Difference between revisions
Content deleted Content added
Deprecating drugbox-mab |
Anypodetos (talk | contribs) m Omnitarg is trade name |
||
| Line 1: | Line 1: | ||
{{drugbox | |
{{drugbox | |
||
| type |
| type = mab |
||
| image = |
| image = |
||
| source = [[Human]] |
| source = [[Human]] |
||
| Line 27: | Line 27: | ||
}} |
}} |
||
'''Pertuzumab''' (also called '''2C4''', |
'''Pertuzumab''' (also called '''2C4''', trade name '''Omnitarg''') is a [[monoclonal antibody]]. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to [[HER2]], it inhibits the [[dimer]]ization of HER2 with other HER receptors, which is hypothesized to result in slowed [[cancer|tumor]] growth.<ref name="JCO-deBono"/> Omnitarg is currently being developed by [[Genentech]]. |
||
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.<ref>[http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=8431 Genentech press release] - May 15, 2005</ref> |
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.<ref>[http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=8431 Genentech press release] - May 15, 2005</ref> |
||
Revision as of 09:34, 20 November 2008
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | HER2 |
| Legal status | |
| Legal status | |
Pertuzumab (also called 2C4, trade name Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[2] Omnitarg is currently being developed by Genentech.
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[3]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ a b de Bono, Johann S. (20 January 2007). "Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer". Journal of Clinical Oncology. 25 (3): 257–262. doi:10.1200/JCO.2006.07.0888. PMID 17235043.
- ^ Genentech press release - May 15, 2005